{ "labelLang" : "hun", "responseDate" : "2024-03-29 03:20", "content" : { "otype" : "JournalArticle", "mtid" : 27370454, "status" : "APPROVED", "published" : true, "comment" : "Cited By :65 \n Export Date: 25 July 2019 \n Correspondence Address: Sinclair, A. M.; Oncology Research, Amgen, 1 Amgen Center Drive, Thousand Oaks, CA 91362, United States; email: anguss@amgen.com \n Chemicals/CAS: erythropoietin, 11096-26-7; recombinant erythropoietin, 113427-24-0, 122312-54-3, 130455-76-4, 148363-16-0, 154725-65-2, 879555-13-2", "unhandledTickets" : 0, "oldTimestamp" : "2018-05-06T08:59:24.000+0000", "deleted" : false, "oldId" : 17370454, "lastRefresh" : "2023-10-26T11:21:50.207+0000", "lastModified" : "2018-05-06T08:59:24.000+0000", "created" : "2018-05-06T08:57:50.000+0000", "creator" : { "otype" : "Author", "mtid" : 10012931, "link" : "/api/author/10012931", "label" : "Lőrincz Andrea (Neuroanatómia)", "familyName" : "Lőrincz", "givenName" : "Andrea", "published" : true, "oldId" : 10012931, "snippet" : true }, "lastDuplumSearch" : "2023-06-20T06:59:22.643+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Elliott, S", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 77202601, "link" : "/api/authorship/77202601", "label" : "Elliott, S", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Elliott", "givenName" : "S", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 162370897, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 77202602, "link" : "/api/authorship/77202602", "label" : "Sinclair, AM", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Sinclair", "givenName" : "AM", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 162370896, "snippet" : true } ], "title" : "The effect of erythropoietin on normal and neoplastic cells", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 13960561, "link" : "/api/publicationidentifier/13960561", "label" : "Scopus: 84866748197", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "84866748197", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-84866748197", "published" : false, "oldId" : 17212222, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10020149, "link" : "/api/journal/10020149", "label" : "BIOLOGICS-TARGETS & THERAPY 1177-5475 1177-5491", "pIssn" : "1177-5475", "eIssn" : "1177-5491", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10020149, "snippet" : true }, "volume" : "6", "firstPage" : "163", "lastPage" : "189", "firstPageOrInternalIdForSort" : "163", "pageLength" : 27, "publishedYear" : 2012, "digital" : null, "printed" : null, "sourceYear" : 2018, "packet" : "565746", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : false, "conferencePublication" : null, "nationalOrigin" : null, "missingAuthor" : false, "oaType" : "GOLD", "oaCheckDate" : "2023-10-26", "oaFree" : false, "oaLink" : "https://www.dovepress.com/biologics-targets-and-therapy-journal", "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 6, "citedCount" : 6, "referenceList" : "Krantz, S.B., Erythropoietin (1991) Blood, 77 (3), pp. 419-434; \n\nGlaspy, J., Crawford, J., Vansteenkiste, J., Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes (2010) Br J Cancer, 102 (2), pp. 301-315; \n\nBohlius, J., Tonia, T., Schwarzer, G., Twist and shout: One decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients (2010) Acta Haematol, 125 (1-2), pp. 55-67; \n\nPapayannopoulou, T., Abkowitz, J., D'Andrea, A., Biology of erythropoiesis, erythroid maturation and differentiation (2000) Hematology Basic Principals and Practice, pp. 202-219. , Hoffman R, Benz EJ, Shattil SJ, et al, editors, 3rd ed. Philadelphia: Churchill Livingston; \n\nHunt, J.A., Half-life and rate of synthesis of globin messenger ribonucleic acid. Determination of half-life of messenger ribonucleic acid and its relative synthetic rate in erythroid cells (1974) Biochem J, 138 (3), pp. 487-498; \n\nDev, A., Fang, J., Sathyanarayana, P., Pradeep, A., Emerson, C., Wojchowski, D.M., During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool (2010) Blood, 116 (24), pp. 5334-5346; \n\nGlaser, K., Limarzi, L.R., Poncher, H.G., Cellular composition of the bone marrow in normal infants and children (1950) Pediatrics, 6 (5), pp. 789-824; \n\nSawyer, S.T., Krantz, S.B., Goldwasser, E., Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells (1987) J Biol Chem, 262 (12), pp. 5554-5562; \n\nMigliaccio, G., Migliaccio, A.R., Visser, J.W., Synergism between erythropoietin and interleukin-3 in the induction of hematopoietic stem cell proliferation and erythroid burst colony formation (1988) Blood, 72 (3), pp. 944-951; \n\nBackx, B., Broeders, L., Hoefsloot, L.H., Wognum, B., Lowenberg, B., Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand (1996) Leukemia, 10 (3), pp. 466-472; \n\nSawada, K., Krantz, S.B., Dai, C.H., Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors (1990) J Cell Physiol, 142 (2), pp. 219-230; \n\nSmith, J.A., Exercise, training and red blood cell turnover (1995) Sports Med, 19 (1), pp. 9-31; \n\nEschbach, J.W., The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin (1989) Kidney Int, 35 (1), pp. 134-148; \n\nLaw, M.L., Cai, G.Y., Lin, F.K., Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism (1986) Proc Natl Acad Sci U S A, 83 (18), pp. 6920-6924; \n\nJacobs, K., Shoemaker, C., Rudersdorf, R., Isolation and characterization of genomic and cDNA clones of human erythropoietin (1985) Nature, 313 (6005), pp. 806-810; \n\nLehir, M., Eckardt, K.U., Kaissling, B., Koury, S.T., Kurtz, A., Structure-function correlations in erythropoietin formation and oxygen sensing in the kidney (1991) Klin Wochenschr, 69 (13), pp. 567-575; \n\nEschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial (1987) New Engl J Med, 316 (2), pp. 73-78; \n\nElliott, S., Egrie, J., Browne, J., Control of rHuEPO biological activity: The role of carbohydrate (2004) Exp Hematol, 32 (12), pp. 1146-1155; \n\nEgrie, J.C., Strickland, T.W., Lane, J., Characterization and biological effects of recombinant human erythropoietin (1986) Immunobiology, 172 (3-5), pp. 213-224; \n\nWickrema, A., Krantz, S.B., Winkelmann, J.C., Bondurant, M.C., Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells (1992) Blood, 80 (8), pp. 1940-1949; \n\nKoury, M.J., Bondurant, M.C., Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells (1990) Science, 248 (4953), pp. 378-381; \n\nRogers, H.M., Yu, X., Wen, J., Smith, R., Fibach, E., Noguchi, C.T., Hypoxia alters progression of the erythroid program (2008) Exp Hematol, 36 (1), pp. 17-27; \n\nWang, G.L., Jiang, B.H., Rue, E.A., Semenza, G.L., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O 2 tension (1995) Proc Natl Acad Sci U S A, 92 (12), pp. 5510-5514; \n\nJiang, B.H., Rue, E., Wang, G.L., Roe, R., Semenza, G.L., Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 (1996) J Biol Chem, 271 (30), pp. 17771-17778; \n\nRankin, E.B., Biju, M.P., Liu, Q., Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo (2007) J Clin Invest, 117 (4), pp. 1068-1077; \n\nYamashita, T., Ohneda, O., Sakiyama, A., Iwata, F., Ohneda, K., Fujii-Kuriyama, Y., The microenvironment for erythropoiesis is regulated by HIF-2alpha through VCAM-1 in endothelial cells (2008) Blood, 112 (4), pp. 1482-1492; \n\nKapitsinou, P.P., Liu, Q., Unger, T.L., Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia (2010) Blood, 116 (16), pp. 3039-3048; \n\nPaliege, A., Rosenberger, C., Bondke, A., Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization (2010) Kidney Int, 77 (4), pp. 312-318; \n\nEpstein, A.C., Gleadle, J.M., McNeill, L.A., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation (2001) Cell, 107 (1), pp. 43-54; \n\nMasson, N., Willam, C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation (2001) EMBO J, 20 (18), pp. 5197-5206; \n\nBruick, R.K., McKnight, S.L., A conserved family of prolyl-4-hydroxylases that modify HIF (2001) Science, 294 (5545), pp. 1337-1340; \n\nIvan, M., Kondo, K., Yang, H., HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O 2 sensing (2001) Science, 292 (5516), pp. 464-468; \n\nHon, W.C., Wilson, M.I., Harlos, K., Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL (2002) Nature, 417 (6892), pp. 975-978; \n\nMaxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation (2001) Exp Nephrol, 9 (4), pp. 235-240; \n\nKoury, S.T., Koury, M.J., Bondurant, M.C., Caro, J., Graber, S.E., Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: Correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration (1989) Blood, 74 (2), pp. 645-651; \n\nObara, N., Suzuki, N., Kim, K., Nagasawa, T., Imagawa, S., Yamamoto, M., Repression via the GATA box is essential for tissue-specific erythropoietin gene expression (2008) Blood, 111 (10), pp. 5223-5232; \n\nErslev, A.J., Wilson, J., Caro, J., Erythropoietin titers in anemic, nonuremic patients (1987) J Lab Clin Med, 109 (4), pp. 429-433; \n\nLin, C.S., Lim, S.K., D'Agati, V., Costantini, F., Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis (1996) Genes Dev, 10 (2), pp. 154-164; \n\nMizuno, S., Sasaki, J., Suzuki, C., Kono, H., Kojima, S., Effect of recombinant human erythropoietin administration on peripheral blood neutrophil counts of premature infants (1994) J Pediatr, 124 (3), pp. 467-470; \n\nShannon, K.M., Mentzer, W.C., Abels, R.I., Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study (1991) J Pediatr, 118 (6), pp. 949-955; \n\nWard, C.S., Westwood, N.B., Emmerson, A.J., Pearson, T.C., The in vitro effect of high-dose recombinant human erythropoietin on granulocyte-macrophage colony production in premature infants using a defined serum deprived cell culture system (1992) Br J Haematol, 81 (3), pp. 325-330; \n\nUlich, T.R., Del, C.J., Yin, S.M., Egrie, J.C., The erythropoietic effects of interleukin 6 and erythropoietin in vivo (1991) Exp Hematol, 19 (1), pp. 29-34; \n\nSingbrant, S., Russell, M.R., Jovic, T., Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment (2011) Blood, 117 (21), pp. 5631-5642; \n\nRamsfjell, V., Borge, O.J., Veiby, O.P., Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: Distinct interactions with the ligands for c-kit and FLT3 (1996) Blood, 88 (12), pp. 4481-4492; \n\nMadan, A., Lin, C., Wang, Z., Curtin, P.T., Autocrine stimulation by erythropoietin in transgenic mice results in erythroid proliferation without neoplastic transformation (2003) Blood Cells Mol Dis, 30 (1), pp. 82-89; \n\nFurukawa, T., Narita, M., Sakaue, M., Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor (1997) Br J Haematol, 99 (1), pp. 222-227; \n\nSherwood, J.B., The chemistry and physiology of erythropoietin (1984) Vitam Horm, 41, pp. 161-211; \n\nJelkmann, W., Erythropoietin: Structure, control of production, and function (1992) Physiol Rev, 72 (2), pp. 449-489; \n\nBeru, N., McDonald, J., Lacombe, C., Goldwasser, E., Expression of the erythropoietin gene (1986) Mol Cell Biol, 6 (7), pp. 2571-2575; \n\nBachmann, S., Le, H.M., Eckardt, K.U., Co-localization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin (1993) J Histochem Cytochem, 41 (3), pp. 335-341; \n\nMaxwell, P.H., Osmond, M.K., Pugh, C.W., Identification of the renal erythropoietin-producing cells using transgenic mice (1993) Kidney Int, 44 (5), pp. 1149-1162; \n\nTan, C.C., Eckardt, K.U., Ratcliffe, P.J., Organ distribution of erythropoietin messenger RNA in normal and uremic rats (1991) Kidney Int, 40 (1), pp. 69-76; \n\nSemenza, G.L., Koury, S.T., Nejfelt, M.K., Gearhart, J.D., Antonarakis, S.E., Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice (1991) Proc Natl Acad Sci U S A, 88 (19), pp. 8725-8729; \n\nFandrey, J., Bunn, H.F., In vivo and in vitro regulation of erythropoietin mRNA: Measurement by competitive polymerase chain reaction (1993) Blood, 81 (3), pp. 617-623; \n\nSuzuki, N., Obara, N., Yamamoto, M., Use of gene-manipulated mice in the study of erythropoietin gene expression (2007) Methods Enzymol, 435, pp. 157-177; \n\nDavid, R.B., Lim, G.B., Moritz, K.M., Koukoulas, I., Wintour, E.M., Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus (2002) Mol Cell Endocrinol, 188 (1-2), pp. 207-218; \n\nBondurant, M.C., Koury, M.J., Koury, S.T., Semenza, G., Erythropoietin ontogeny and organ distribution in mice (1991) Semin Hematol, 28 (3 SUPPL 3), pp. 20-25; \n\nErslev, A.J., Caro, J., Kansu, E., Silver, R., Renal and extrarenal erythropoietin production in anaemic rats (1980) Br J Haematol, 45 (1), pp. 65-72; \n\nBondurant, M.C., Koury, M.J., Anemia induces accumulation of erythropoietin mRNA in the kidney and liver (1986) Mol Cell Biol, 6 (7), pp. 2731-2733; \n\nEckardt, K.U., Ratcliffe, P.J., Tan, C.C., Bauer, C., Kurtz, A., Age-dependent expression of the erythropoietin gene in rat liver and kidneys (1992) J Clin Invest, 89 (3), pp. 753-760; \n\nKoury, S.T., Bondurant, M.C., Koury, M.J., Semenza, G.L., Localization of cells producing erythropoietin in murine liver by in situ hybridization (1991) Blood, 77 (11), pp. 2497-2503; \n\nFrede, S., Freitag, P., Geuting, L., Konietzny, R., Fandrey, J., Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC (2011) Blood, 117 (18), pp. 4905-4914; \n\nLoya, F., Yang, Y., Lin, H., Goldwasser, E., Albitar, M., Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia (1994) Blood, 84 (6), pp. 1831-1836; \n\nJeong, J.Y., Feldman, L., Solar, P., Szenajch, J., Sytkowski, A.J., Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells (2008) Int J Cancer, 122 (2), pp. 274-280; \n\nJeong, J.Y., Hoxhaj, G., Socha, A.L., Sytkowski, A.J., Feldman, L., An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells (2009) Mol Cancer Res, 7 (7), pp. 1150-1157; \n\nAcs, G., Zhang, P.J., Rebbeck, T.R., Acs, P., Verma, A., Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma (2002) Cancer, 95 (5), pp. 969-981; \n\nGombos, Z., Danihel, L., Repiska, V., Acs, G., Furth, E., Expression of erythropoietin and its receptor increases in colonic neoplastic progression: The role of hypoxia in tumorigenesis (2011) Indian J Pathol Microbiol, 54 (2), pp. 273-278; \n\nSanchez, P.E., Navarro, F.P., Fares, R.P., Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span (2009) J Comp Neurol, 514 (4), pp. 403-414; \n\nCastillo-Melendez, M., Yan, E., Walker, D.W., Expression of erythropoietin and its receptor in the brain of late-gestation fetal sheep, and responses to asphyxia caused by umbilical cord occlusion (2005) Dev Neurosci, 27 (2-4), pp. 220-227; \n\nChung, Y.H., Kim, S.I., Joo, K.M., Age-related changes in erythropoietin immunoreactivity in the cerebral cortex and hippocampus of rats (2004) Brain Res, 1018 (1), pp. 141-146; \n\nKnabe, W., Knerlich, F., Washausen, S., Expression patterns of erythropoietin and its receptor in the developing midbrain (2004) Anat Embryol (Berl), 207 (6), pp. 503-512; \n\nWinkelmann, J.C., Penny, L.A., Deaven, L.L., Forget, B.G., Jenkins, R.B., The gene for the human erythropoietin receptor: Analysis of the coding sequence and assignment to chromosome 19p (1990) Blood, 76 (1), pp. 24-30; \n\nJones, S.S., D'Andrea, A.D., Haines, L.L., Wong, G.G., Human erythropoietin receptor: Cloning, expression, and biologic characterization (1990) Blood, 76 (1), pp. 31-35; \n\nD'Andrea, A.D., Lodish, H.F., Wong, G.G., Expression cloning of the murine erythropoietin receptor (1989) Cell, 57 (2), pp. 277-285; \n\nBudarf, M., Huebner, K., Emanuel, B., Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19 (1990) Genomics, 8 (3), pp. 575-578; \n\nElliott, S., Busse, L., Bass, M.B., Anti-Epo receptor antibodies do not predict Epo receptor expression (2006) Blood, 107 (5), pp. 1892-1895; \n\nAtkins, H.L., Broudy, V.C., Papayannopoulou, T., Characterization of the structure of the erythropoietin receptor by ligand blotting (1991) Blood, 77 (12), pp. 2577-2582; \n\nElliott, S., Busse, L., McCaffery, I., Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells (2010) J Immunol Methods, 352, pp. 126-139; \n\nKetteler, R., Heinrich, A.C., Offe, J.K., A functional green fluorescent protein-erythropoietin receptor despite physical separation of JAK2 binding site and tyrosine residues (2002) J Biol Chem, 277 (29), pp. 26547-26552; \n\nSwift, S., Ellison, A.R., Kassner, P., Absence of functional EpoR expression in human tumor cell lines (2010) Blood, 115 (21), pp. 4254-4263; \n\nNeumann, D., Wikstrom, L., Watowich, S.S., Lodish, H.F., Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes (1993) J Biol Chem, 268 (18), pp. 13639-13649; \n\nHilton, D.J., Watowich, S.S., Murray, P.J., Lodish, H.F., Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor (1995) Proc Natl Acad Sci U S A, 92 (1), pp. 190-194; \n\nSupino-Rosin, L., Yoshimura, A., Altaratz, H., Neumann, D., A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation (1999) Eur J Biochem, 263 (2), pp. 410-419; \n\nBillia, F., Barbara, M., McEwen, J., Trevisan, M., Iscove, N.N., Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: Confirmation of assignments by expression profiling of cytokine receptor transcripts (2001) Blood, 97 (8), pp. 2257-2268; \n\nLiu, Z.Y., Chin, K., Noguchi, C.T., Tissue specific expression of human erythropoietin receptor in transgenic mice (1994) Dev Biol, 166 (1), pp. 159-169; \n\nChiba, T., Ikawa, Y., Todokoro, K., GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression (1991) Nucleic Acids Res, 19 (14), pp. 3843-3848; \n\nHeberlein, C., Fischer, K.D., Stoffel, M., The gene for erythropoietin receptor is expressed in multipotential hematopoietic and embryonal stem cells: Evidence for differentiation stage-specific regulation (1992) Mol Cell Biol, 12 (4), pp. 1815-1826; \n\nHeinrich, A.C., Pelanda, R., Klingmuller, U., A mouse model for visualization and conditional mutations in the erythroid lineage (2004) Blood, 104 (3), pp. 659-666; \n\nAshihara, E., Vannucchi, A.M., Migliaccio, G., Migliaccio, A.R., Growth factor receptor expression during in vitro differentiation of partially purified populations containing murine stem cells (1997) J Cell Physiol, 171 (3), pp. 343-356; \n\nChiba, S., Takahashi, T., Takeshita, K., Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera (1997) Blood, 90 (1), pp. 97-104; \n\nLaugsch, M., Metzen, E., Svensson, T., Depping, R., Jelkmann, W., Lack of functional erythropoietin receptors of cancer cell lines (2008) Int J Cancer, 122 (5), pp. 1005-1011; \n\nSinclair, A.M., Rogers, N., Busse, L., Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells (2008) Br J Cancer, 98 (6), pp. 1059-1067; \n\nKeller, M.A., Addya, S., Vadigepalli, R., Transcriptional regulatory network analysis of developing human erythroid progenitors reveals patterns of coregulation and potential transcriptional regulators (2006) Physiol Genomics, 28 (1), pp. 114-128; \n\nSinclair, A.M., Coxon, A., McCaffery, I., Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells (2010) Blood, 115 (21), pp. 4264-4272; \n\nHardee, M.E., Arcasoy, M.O., Blackwell, K.L., Kirkpatrick, J.P., Dewhirst, M.W., Erythropoietin biology in cancer (2006) Clin Cancer Res, 12 (2), pp. 332-339; \n\nKokhaei, P., Abdalla, A.O., Hansson, L., Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies (2007) Clin Cancer Res, 13 (12), pp. 3536-3544; \n\nBrown, W.M., Maxwell, P., Graham, A.N., Erythropoietin receptor expression in non-small cell lung carcinoma: A question of antibody specificity (2007) Stem Cells, 25 (3), pp. 718-722; \n\nKirkeby, A., Van, B.J., Nielsen, J., Leist, M., Helboe, L., Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor (2007) J Neurosci Methods, 164 (1), pp. 50-58; \n\nSinclair, A.M., Todd, M.D., Forsythe, K., Knox, S.J., Elliott, S., Begley, C.G., Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients (2007) Cancer, 110 (3), pp. 477-488; \n\nOsterborg, A., Aapro, M., Cornes, P., Haselbeck, A., Hayward, C.R., Jelkmann, W., Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia (2007) Eur J Cancer, 43 (3), pp. 510-519; \n\nKirkpatrick, P., Specificity concerns with antibodies for receptor mapping (2009) Nat Rev Drug Discov, 8 (4), p. 278; \n\nBordeaux, J., Welsh, A., Agarwal, S., Antibody validation (2010) Biotechniques, 48 (3), pp. 197-209; \n\nBroudy, V.C., Lin, N., Egrie, J., Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide (1988) Proc Natl Acad Sci U S A, 85 (17), pp. 6513-6517; \n\nBroudy, V.C., Lin, N., Brice, M., Nakamoto, B., Papayannopoulou, T., Erythropoietin receptor characteristics on primary human erythroid cells (1991) Blood, 77 (12), pp. 2583-2590; \n\nRadinsky, R., Risin, S., Fan, D., Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells (1995) Clin Cancer Res, 1 (1), pp. 19-31; \n\nFoon, K.A., Yang, X.D., Weiner, L.M., Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody (2004) Int J Radiat Oncol Biol Phys, 58 (3), pp. 984-990; \n\nSasaki, R., Yanagawa, S., Hitomi, K., Chiba, H., Characterization of erythropoietin receptor of murine erythroid cells (1987) Eur J Biochem, 168 (1), pp. 43-48; \n\nMcArthur, G.A., Longmore, G.D., Klingler, K., Johnson, G.R., Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR (1995) Exp Hematol, 23 (7), pp. 645-654; \n\nSawada, K., Krantz, S.B., Sawyer, S.T., Civin, C.I., Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells (1988) J Cell Physiol, 137 (2), pp. 337-345; \n\nWognum, A.W., Lansdorp, P.M., Humphries, R.K., Krystal, G., Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin (1990) Blood, 76 (4), pp. 697-705; \n\nWognum, A.W., Krystal, G., Eaves, C.J., Eaves, A.C., Lansdorp, P.M., Increased erythropoietin-receptor expression on CD34-positive bone marrow cells from patients with chronic myeloid leukemia (1992) Blood, 79 (3), pp. 642-649; \n\nShinjo, K., Takeshita, A., Higuchi, M., Ohnishi, K., Ohno, R., Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assay (1997) Br J Haematol, 96 (3), pp. 551-558; \n\nMayeux, P., Billat, C., Jacquot, R., The erythropoietin receptor of rat erythroid progenitor cells. Characterization and affinity cross-linkage (1987) J Biol Chem, 262 (29), pp. 13985-13990; \n\nHoshino, S., Teramura, M., Takahashi, M., Expression and characterization of erythropoietin receptors on normal human bone marrow cells (1989) Int J Cell Cloning, 7 (3), pp. 156-167; \n\nFraser, J.K., Lin, F.K., Berridge, M.V., Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line (1988) HEL. Exp Hematol, 16 (10), pp. 836-842; \n\nWu, H., Liu, X., Jaenisch, R., Lodish, H.F., Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor (1995) Cell, 83 (1), pp. 59-67; \n\nMitjavila, M.T., Natazawa, M., Brignaschi, P., Debili, N., Breton-Gorius, J., Vainchenker, W., Effects of five recombinant hematopoietic growth factors on enriched human erythroid progenitors in serum-replaced cultures (1989) J Cell Physiol, 138 (3), pp. 617-623; \n\nCull, V., Tilbrook, P.A., Adenan, A.S., Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo (2000) Oncogene, 19 (7), pp. 953-960; \n\nHuang, L.J., Constantinescu, S.N., Lodish, H.F., The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor (2001) Mol Cell, 8 (6), pp. 1327-1338; \n\nWickrema, A., Bondurant, M.C., Krantz, S.B., Abundance and stability of erythropoietin receptor mRNA in mouse erythroid progenitor cells (1991) Blood, 78 (9), pp. 2269-2275; \n\nLodish, H.F., Hilton, D., Longmore, G., Watowich, S.S., Yoshimura, A., The erythropoietin receptor: Dimerization, activation, and tumorigenesis (1992) Cold Spring Harb Symp Quant Biol, 57, pp. 95-106; \n\nYoussoufian, H., Zon, L.I., Orkin, S.H., D'Andrea, A.D., Lodish, H.F., Structure and transcription of the mouse erythropoietin receptor gene (1990) Mol Cell Biol, 10 (7), pp. 3675-3682; \n\nZon, L.I., Youssoufian, H., Mather, C., Lodish, H.F., Orkin, S.H., Activation of the erythropoietin receptor promoter by transcription factor GATA-1 (1991) Proc Natl Acad Sci U S A, 88 (23), pp. 10638-10641; \n\nMaouche, L., Cartron, J.P., Chretien, S., Different domains regulate the human erythropoietin receptor gene transcription (1994) Nucleic Acids Res, 22 (3), pp. 338-346; \n\nYoussoufian, H., Further characterization of cis-acting regulatory sequences in the genomic locus of the murine erythropoietin receptor: Evidence for stage-specific regulation (1994) Blood, 83 (5), pp. 1428-1435; \n\nKuramochi, S., Ikawa, Y., Todokoro, K., Characterization of murine erythropoietin receptor genes (1990) J Mol Biol, 216 (3), pp. 567-575; \n\nSingbrant, S., Russell, M.R., Jovic, Erythropoietin couples erythropoiesis, B lymphopoiesis, and bone homeostasis within the bone marrow microenvironment (2011) Blood, 117 (21), pp. 5631-5642; \n\nHagstrom, L., Agbulut, O., El-Hasnaoui-Saadani, R., Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia (2010) J Biomed Biotechnol, p. 2010. , 137817; \n\nBanerjee, D., Rodriguez, M., Nag, M., Adamson, J.W., Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity (2000) Kidney Int, 57 (5), pp. 1895-1904; \n\nOhigashi, T., Yoshioka, K., Fisher, J.W., Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells (1996) Life Sci, 58 (5), pp. 421-427; \n\nDigicaylioglu, M., Bichet, S., Marti, H.H., Localization of specific erythropoietin binding sites in defined areas of the mouse brain (1995) Proc Natl Acad Sci U S A, 92 (9), pp. 3717-3720; \n\nMohyeldin, A., Dalgard, C.L., Lu, H., Survival and invasiveness of astrocytomas promoted by erythropoietin (2007) J Neurosurg, 106 (2), pp. 338-350; \n\nBramey, T., Freitag, P., Fandrey, J., No evidence for protective erythropoietin alpha signalling in rat hepatocytes (2009) BMC Gastroenterol, 9, p. 26; \n\nWinter, S.C., Shah, K.A., Campo, L., Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma (2005) Clin Cancer Res, 11 (21), pp. 7614-7620; \n\nBernaudin, M., Bellail, A., Marti, H.H., Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain (2000) Glia, 30 (3), pp. 271-278; \n\nWincewicz, A., Koda, M., Sulkowska, M., Kanczuga-Koda, L., Wincewicz, D., Sulkowski, S., STAT3 and hypoxia induced proteins - HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers (2009) Folia Histochem Cytobiol, 47 (3), pp. 425-430; \n\nBatra, S., Perelman, N., Luck, L.R., Shimada, H., Malik, P., Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival (2003) Lab Invest, 83 (10), pp. 1477-1487; \n\nLam, S.Y., Tipoe, G.L., Fung, M.L., Upregulation of erythropoietin and its receptor expression in the rat carotid body during chronic and intermittent hypoxia (2009) Adv Exp Med Biol, 648, pp. 207-214; \n\nChen, Z.Y., Wang, L., Asavaritkrai, P., Noguchi, C.T., Up-regulation of erythropoietin receptor by nitric oxide mediates hypoxia preconditioning (2010) J Neurosci Res, 88 (14), pp. 3180-3188; \n\nAcs, G., Acs, P., Beckwith, S.M., Erythropoietin and erythropoietin receptor expression in human cancer (2001) Cancer Res, 61 (9), pp. 3561-3565; \n\nPevny, L., Lin, C.S., D'Agati, V., Simon, M.C., Orkin, S.H., Costantini, F., Development of hematopoietic cells lacking transcription factor GATA-1 (1995) Development, 121 (1), pp. 163-172; \n\nPevny, L., Simon, M.C., Robertson, E., Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1 (1991) Nature, 349 (6306), pp. 257-260; \n\nSimon, M.C., Pevny, L., Wiles, M.V., Keller, G., Costantini, F., Orkin, S.H., Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells (1992) Nat Genet, 1 (2), pp. 92-98; \n\nKomatsu, N., Kirito, K., Kashii, Y., Cell-cycle-dependent regulation of erythropoietin receptor gene (1997) Blood, 89 (4), pp. 1182-1188; \n\nSuzuki, N., Suwabe, N., Ohneda, O., Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels (2003) Blood, 102 (10), pp. 3575-3583; \n\nCrotta, S., Nicolis, S., Ronchi, A., Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines (1990) Nucleic Acids Res, 18 (23), pp. 6863-6869; \n\nMigliaccio, A.R., Migliaccio, G., D'Andrea, A., Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface (1991) Proc Natl Acad Sci U S A, 88 (24), pp. 11086-11090; \n\nTsang, A.P., Fujiwara, Y., Hom, D.B., Orkin, S.H., Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG (1998) Genes Dev, 12 (8), pp. 1176-1188; \n\nSnow, J.W., Orkin, S.H., Translational isoforms of FOG1 regulate GATA1-interacting complexes (2009) J Biol Chem, 284 (43), pp. 29310-29319; \n\nKassouf, M.T., Hughes, J.R., Taylor, S., Genome-wide identification of TAL1's functional targets: Insights into its mechanisms of action in primary erythroid cells (2010) Genome Res, 20 (8), pp. 1064-1083; \n\nMikkola, H.K., Klintman, J., Yang, H., Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene (2003) Nature, 421 (6922), pp. 547-551; \n\nGreen, A.R., Salvaris, E., Begley, C.G., Erythroid expression of the 'helix-loop-helix' gene, SCL (1991) Oncogene, 6 (3), pp. 475-479; \n\nVisvader, J., Begley, C.G., Adams, J.M., Differential expression of the LYL, SCL and E2 A helix-loop-helix genes within the hemopoietic system (1991) Oncogene, 6 (2), pp. 187-194; \n\nInthal, A., Krapf, G., Beck, D., Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia (2008) Clin Cancer Res, 14 (22), pp. 7196-7204; \n\nGreen, A.R., Lints, T., Visvader, J., Harvey, R., Begley, C.G., SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain (1992) Oncogene, 7 (4), pp. 653-660; \n\nMaouche, L., Cartron, J.P., Chretien, S., Different domains regulate the human erythropoietin receptor gene transcription (1994) Nucleic Acids Res, 22 (3), pp. 338-346; \n\nNoguchi, C.T., Bae, K.S., Chin, K., Wada, Y., Schechter, A.N., Hankins, W.D., Cloning of the human erythropoietin receptor gene (1991) Blood, 78 (10), pp. 2548-2556; \n\nPhilo, J.S., Aoki, K.H., Arakawa, T., Narhi, L.O., Wen, J., Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction (1996) Biochemistry, 35 (5), pp. 1681-1691; \n\nSyed, R.S., Reid, S.W., Li, C., Efficiency of signalling through cytokine receptors depends critically on receptor orientation (1998) Nature, 395 (6701), pp. 511-516; \n\nWatowich, S.S., Activation of erythropoietin signaling by receptor dimerization (1999) Int J Biochem Cell Biol, 31 (10), pp. 1075-1088; \n\nGross, A.W., Lodish, H.F., Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP) (2006) J Biol Chem, 281 (4), pp. 2024-2032; \n\nBeckman, D.L., Lin, L.L., Quinones, M.E., Longmore, G.D., Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin (1999) Blood, 94 (8), pp. 2667-2675; \n\nNarhi, L.O., Aoki, K.H., Philo, J.S., Arakawa, T., Changes in conformation and stability upon formation of complexes of erythropoietin (EPO) and soluble EPO receptor (1997) J Protein Chem, 16 (3), pp. 213-225; \n\nRemy, I., Wilson, I.A., Michnick, S.W., Erythropoietin receptor activation by a ligand-induced conformation change (1999) Science, 283 (5404), pp. 990-993; \n\nLu, X., Gross, A.W., Lodish, H.F., Active conformation of the erythropoietin receptor: Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains (2006) J Biol Chem, 281 (11), pp. 7002-7011; \n\nWojchowski, D.M., Gregory, R.C., Miller, C.P., Pandit, A.K., Pircher, T.J., Signal transduction in the erythropoietin receptor system (1999) Exp Cell Res, 253 (1), pp. 143-156; \n\nJegalian, A.G., Wu, H., Differential roles of SOCS family members in EpoR signal transduction (2002) J Interferon Cytokine Res, 22 (8), pp. 853-860; \n\nMinoo, P., Zadeh, M.M., Rottapel, R., Lebrun, J.J., Ali, S., A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: Contribution of SHP-1 C-terminal tyrosines in cytokine signaling (2004) Blood, 103 (4), pp. 1398-1407; \n\nVerdier, F., Walrafen, P., Hubert, N., Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors (2000) J Biol Chem, 275 (24), pp. 18375-18381; \n\nKubatzky, K.F., Ruan, W., Gurezka, R., Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor (2001) Curr Biol, 11 (2), pp. 110-115; \n\nBinder, C., Lafayette, A., Archibeque, I., Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign (2008) Assay Drug Dev Technol, 6 (1), pp. 27-37; \n\nTakahashi, T., Chiba, S., Hirano, N., Yazaki, Y., Hirai, H., Characterization of three erythropoietin (Epo)-binding proteins in various human Epo-responsive cell lines and in cells transfected with human Epo-receptor cDNA (1995) Blood, 85 (1), pp. 106-114; \n\nSantucci, M.A., Pierce, J.H., Zannini, S., Erythropoietin increases the radioresistance of a clonal hematopoietic progenitor cell line expressing a transgene for the erythropoietin receptor (1994) Stem Cells, 12 (5), pp. 506-513; \n\nYawata, H., Yasukawa, K., Natsuka, S., Structure-function analysis of human IL-6 receptor: Dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130 (1993) EMBO J, 12 (4), pp. 1705-1712; \n\nJegalian, A.G., Acurio, A., Dranoff, G., Wu, H., Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3 (2002) Blood, 99 (7), pp. 2603-2605; \n\nUm, M., Gross, A.W., Lodish, H.F., A \"classical\" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells (2007) Cell Signal, 19 (3), pp. 634-645; \n\nPregi, N., Vittori, D., Perez, G., Leiros, C.P., Nesse, A., Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells (2006) Biochim Biophys Acta, 1763 (2), pp. 238-246; \n\nRossler, J., Stolze, I., Frede, S., Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site (2004) J Cell Biochem, 93 (1), pp. 153-161; \n\nDrexler, H.G., Matsuo, Y., Macleod, R.A., Malignant hematopoietic cell lines: In vitro models for the study of erythroleukemia (2004) Leuk Res, 28 (12), pp. 1243-1251; \n\nTodokoro, K., Kanazawa, S., Amanuma, H., Ikawa, Y., Characterization of erythropoietin receptor on erythropoietin-unresponsive mouse erythroleukemia cells (1988) Biochim Biophys Acta, 943 (2), pp. 326-330; \n\nMayeux, P., Billat, C., Jacquot, R., Murine erythroleukaemia cells (Friend cells) possess high-affinity binding sites for erythropoietin (1987) FEBS Lett, 211 (2), pp. 229-233; \n\nEhrenman, K., St, J.T., The erythropoietin receptor gene: Cloning and identification of multiple transcripts in an erythroid cell line OCIM1 (1991) Exp Hematol, 19 (9), pp. 973-977; \n\nZou, X., Calame, K., Signaling pathways activated by oncogenic forms of Abl tyrosine kinase (1999) J Biol Chem, 274 (26), pp. 18141-18144; \n\nLozzio, C.B., Lozzio, B.B., Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome (1975) Blood, 45 (3), pp. 321-334; \n\nElliott, S., Busse, L., Swift, S., Lack of expression and function of erythropoietin receptors in kidney. Nephrol Dial Transplant. 2012 (2011) Epub December, p. 13; \n\nGaffen, S.L., Lai, S.Y., Longmore, G.D., Liu, K.D., Goldsmith, M.A., Genetic evidence for an additional factor required for erythropoietin-induced signal transduction (1999) Blood, 94 (1), pp. 74-86; \n\nD'Andrea, A.D., Jones, S.S., Activation of the erythropoietin receptor in stable lymphoid and myeloid transfectants (1991) Semin Hematol, 28 (2), pp. 152-157; \n\nShikama, Y., Barber, D.L., D'Andrea, A.D., Sieff, C.A., A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines (1996) Blood, 88 (2), pp. 455-464; \n\nWakao, H., Harada, N., Kitamura, T., Mui, A.L., Miyajima, A., Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways (1995) EMBO J, 14 (11), pp. 2527-2535; \n\nYamamura, Y., Kageyama, Y., Matuzaki, T., Noda, M., Ikawa, Y., Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor (1992) EMBO J, 11 (13), pp. 4909-4915; \n\nMinamoto, S., Treisman, J., Hankins, W.D., Sugamura, K., Rosenberg, S.A., Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors (1995) Blood, 86 (6), pp. 2281-2287; \n\nLongmore, G.D., Lodish, H.F., An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: A cytokine receptor superfamily oncogene (1991) Cell, 67 (6), pp. 1089-1102; \n\nKang, J.K., Chang, C.H., Nam, H.J., Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells (2011) Cell Oncol, 34 (1), pp. 11-21; \n\nLayon, M.E., Ackley, C.J., West, R.J., Lowrey, C.H., Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression (2007) J Mol Biol, 366 (3), pp. 737-744; \n\nMiura, Y., Miura, O., Ihle, J.N., Aoki, N., Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor (1994) J Biol Chem, 269 (47), pp. 29962-29969; \n\nZhan, X., Goldfarb, M., Growth factor requirements of oncogene-transformed NIH 3T3 and BALB/c 3T3 cells cultured in defined media (1986) Mol Cell Biol, 6 (10), pp. 3541-3544; \n\nPharr, P.N., Ogawa, M., Hofbauer, A., Longmore, G.D., Expression of an activated erythropoietin or a colony-stimulating factor 1 receptor by pluripotent progenitors enhances colony formation but does not induce differentiation (1994) Proc Natl Acad Sci U S A, 91 (16), pp. 7482-7486; \n\nLongmore, G.D., Pharr, P., Neumann, D., Lodish, H.F., Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor (1993) Blood, 82 (8), pp. 2386-2395; \n\nLongmore, G.D., Pharr, P.N., Lodish, H.F., A constitutively activated erythropoietin receptor stimulates proliferation and contributes to transformation of multipotent, committed nonerythroid and erythroid progenitor cells (1994) Mol Cell Biol, 14 (4), pp. 2266-2277; \n\nHenke, M., Laszig, R., Rube, C., Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial (2003) Lancet, 362 (9392), pp. 1255-1260; \n\nHenke, M., Mattern, D., Pepe, M., Do erythropoietin receptors on cancer cells explain unexpected clinical findings? (2006) J Clin Oncol, 24 (29), pp. 4708-4713; \n\nMcKinney, M., Arcasoy, M.O., Erythropoietin for oncology supportive care (2011) Exp Cell Res, 317, pp. 1246-1254. , (9 Special Issue SI); \n\nSzenajch, J., Wcislo, G., Jeong, J.Y., Szczylik, C., Feldman, L., The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. From clinic to bench - a critical review (2010) Biochim Biophys Acta, 1806 (1), pp. 82-95; \n\nJelkmann, W., Bohlius, J., Hallek, M., Sytkowski, A.J., The erythropoietin receptor in normal and cancer tissues (2008) Crit Rev Oncol Hematol, 67 (1), pp. 39-61; \n\nNowrousian, M.R., Dunst, J., Vaupel, P., Erythropoiesis-stimulating agents: Favorable safety profile when used as indicated (2008) Strahlenther Onkol, 184 (3), pp. 121-136; \n\nHadland, B.K., Longmore, G.D., Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms (2009) J Clin Oncol, (25), pp. 4217-4226; \n\nWinkelmann, J.C., Ward, J., Mayeux, P., Lacombe, C., Schimmenti, L., Jenkins, R.B., A translocated erythropoietin receptor gene in a human erythroleukemia cell line (TF-1) expresses an abnormal transcript and a truncated protein (1995) Blood, 85 (1), pp. 179-185; \n\nChretien, S., Moreau-Gachelin, F., Apiou, F., Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells (1994) Blood, 83 (7), pp. 1813-1821; \n\nGonda, T.J., D'Andrea, R.J., Activating mutations in cytokine receptors: Implications for receptor function and role in disease (1997) Blood, 89 (2), pp. 355-369; \n\nLe Couedic, J.P., Mitjavila, M.T., Villeval, J.L., Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies (1996) Blood, 87 (4), pp. 1502-1511; \n\nD'Andrea, A.D., Moreau, J.F., Showers, M.O., Molecular mimicry of erythropoietin by the spleen focus-forming virus gp55 glycoprotein: The first stage of Friend virus-induced erythroleukemia (1992) Biochim Biophys Acta, 1114 (1), pp. 31-41; \n\nMoreau-Gachelin, F., Multi-stage Friend murine erythroleukemia: Molecular insights into oncogenic cooperation (2008) Retrovirology, 5, p. 99; \n\nYoshimura, A., Longmore, G., Lodish, H.F., Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity (1990) Nature, 348 (6302), pp. 647-649; \n\nRives, S., Pahl, H.L., Florensa, L., Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis (2007) Haematologica, 92 (5), pp. 674-677; \n\nAl-Sheikh, M., Mazurier, E., Gardie, B., A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene (2008) Haematologica, 93 (7), pp. 1072-1075; \n\nWatowich, S.S., Xie, X., Klingmuller, U., Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state (1999) Blood, 94 (7), pp. 2530-2532; \n\nde la Chapelle, A., Traskelin, A.L., Juvonen, E., Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis (1993) Proc Natl Acad Sci U S A, 90 (10), pp. 4495-4499; \n\nGordeuk, V.R., Sergueeva, A.I., Miasnikova, G.Y., Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors (2004) Blood, 103 (10), pp. 3924-3932; \n\nAcs, G., Zhang, P.J., McGrath, C.M., Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression (2003) Am J Pathol, 162 (6), pp. 1789-1806; \n\nArcasoy, M.O., Jiang, X., Haroon, Z.A., Expression of erythropoietin receptor splice variants in human cancer (2003) Biochem Biophys Res Commun, 307 (4), pp. 999-1007; \n\nBatra, S., Perelman, N., Luck, L.R., Shimada, H., Malik, P., Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival (2003) Lab Invest, 83 (10), pp. 1477-1487; \n\nFeldman, L., Wang, Y., Rhim, J.S., Bhattacharya, N., Loda, M., Sytkowski, A.J., Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells (2006) Prostate, 66 (2), pp. 135-145; \n\nKataoka, M., Moriya, Y., Moriguchi, Y., Effect of erythropoietin on human tumor growth in xenograft models (2010) Mol Med Report, 3 (1), pp. 95-101; \n\nLai, S.Y., Childs, E.E., Xi, S., Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma (2005) Oncogene, 24 (27), pp. 4442-4449; \n\nLarsson, A.M., Jirstrom, K., Fredlund, E., Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer (2009) Clin Cancer Res, 15 (17), pp. 5552-5559; \n\nWestphal, G., Niederberger, E., Blum, C., Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality (2002) Tumori, 88 (2), pp. 150-159; \n\nYasuda, Y., Fujita, Y., Matsuo, T., Erythropoietin regulates tumour growth of human malignancies (2003) Carcinogenesis, 24 (6), pp. 1021-1029; \n\nYasuda, Y., Fujita, Y., Masuda, S., Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs (2002) Carcinogenesis, 23 (11), pp. 1797-1805; \n\nShi, Z., Hodges, V.M., Dunlop, E.A., Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line (2010) Mol Cancer Res, 8 (4), pp. 615-626; \n\nMiller, C.P., Lowe, K.A., Valliant-Saunders, K., Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial (2009) Stem Cells, 27 (9), pp. 2353-2361; \n\nNing, S., Hartley, C., Molineux, G., Knox, S.J., Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia (2005) Cancer Res, 65 (1), pp. 284-290; \n\nParagh, G., Kumar, S.M., Rakosy, Z., Choi, S.C., Xu, X., Acs, G., RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells (2009) Am J Pathol, 174 (4), pp. 1504-1514; \n\nSasaki, Y., Kjellen, E., Mineta, H., Wennerberg, J., Ekblad, L., No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo (2009) Acta Oncol, 48 (7), pp. 1062-1069; \n\nWilliams, D.M., Zimmers, T.A., Pierce, J.H., The expression and role of human erythropoietin receptor in erythroid and nonerythroid cells (1994) Ann N Y Acad Sci, 718, pp. 232-243; \n\nMasuda, S., Nagao, M., Takahata, K., Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells (1993) J Biol Chem, 268 (15), pp. 11208-11216; \n\nSaintigny, P., Besse, B., Callard, P., Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer (2007) Clin Cancer Res, 13 (16), pp. 4825-4831; \n\nBelda-Iniesta, C., Perona, R., Carpeno, J.C., Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells (2007) Cancer Biol Ther, 6 (10), pp. 1600-1605; \n\nMcBroom, J.W., Acs, G., Rose, G.S., Krivak, T.C., Mohyeldin, A., Verma, A., Erythropoietin receptor function and expression in epithelial ovarian carcinoma (2005) Gynecol Oncol, 99 (3), pp. 571-577; \n\nRades, D., Setter, C., Dahl, O., Schild, S.E., Noack, F., Prognostic Impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage ii/iii non-small-cell lung cancer (2011) Int J Radiat Oncol Biol Phys, 80 (2), pp. 499-505; \n\nRades, D., Golke, H., Schild, S.E., Kilic, E., The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation (2008) Int J Radiat Oncol Biol Phys, 71 (1), pp. 152-159; \n\nRibatti, D., Marzullo, A., Nico, B., Crivellato, E., Ria, R., Vacca, A., Erythropoietin as an angiogenic factor in gastric carcinoma (2003) Histopathology, 42 (3), pp. 246-250; \n\nRibatti, D., Nico, B., Perra, M.T., Erythropoietin is involved in angiogenesis in human primary melanoma (2010) Int J Exp Pathol, 91 (6), pp. 495-499; \n\nBrunotte, J., Bock, H.C., Bruck, W., Hemmerlein, B., Strik, H., High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma (2011) Exp Ther Med, 2 (2), pp. 295-299; \n\nLonnroth, C., Svensson, M., Wang, W., Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care (2008) Med Oncol, 25 (1), pp. 22-29; \n\nMittelbronn, M., Capper, D., Bunz, B., De novo erythropoietin receptor (EPO-R. expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival (2007) Neuropathol Appl Neurobiol, 33 (3), pp. 299-307; \n\nPelekanou, V., Kampa, M., Kafousi, M., Erythropoietin and its receptor in breast cancer: Correlation with steroid receptors and outcome (2007) Cancer Epidemiol Biomarkers Prev, 16 (10), pp. 2016-2023; \n\nSartelet, H., Fabre, M., Castaing, M., Expression of erythropoietin and its receptor in neuroblastomas (2007) Cancer, 110 (5), pp. 1096-1106; \n\ndella Ragione, F., Cucciolla, V., Borriello, A., Oliva, A., Perrotta, S., Erythropoietin receptors on cancer cells: A still open question (2007) J Clin Oncol, 25 (13), pp. 1812-1813; \n\nSturiale, A., Campo, S., Crasci, E., Erythropoietin and its lost receptor (2007) Nephrol Dial Transplant, 22 (5), pp. 1484-1485; \n\nLorincz, A., Nusser, Z., Specificity of immunoreactions: The importance of testing specificity in each method (2008) J Neurosci, 28 (37), pp. 9083-9086; \n\nLeong, A.S., Pitfalls in diagnostic immunohistology (2004) Adv Anat Pathol, 11 (2), pp. 86-93; \n\nBordeaux, J., Welsh, A., Agarwal, S., Antibody validation (2010) Biotechniques, 48 (3), pp. 197-209; \n\nSaper, C.B., A guide to the perplexed on the specificity of antibodies (2009) J Histochem Cytochem, 57 (1), pp. 1-5; \n\nFritschy, J.M., Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry (2008) Eur J Neurosci, 28 (12), pp. 2365-2370; \n\nElliott, S., Swift, S., Busse, L., Rossi, J., McCaffery, I., Absence of functional Epo receptors in normal and cancerous human tissues and cell lines (2011) Blood, 118 (21), p. 3169; \n\nRossi, J., McCaffery, I., Paweletz, K., Analysis of cell surface erythropoietin receptor (EpoR) expression and function in human epithelial tumor tissues [abstract] (2009) J Clin Onco, 27 (15 S). , Abstr 11104; \n\nTakeshita, A., Shinjo, K., Higuchi, M., Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: Relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group (2000) Br J Haematol, 108 (1), pp. 55-63; \n\nKokhaei, P., Abdalla, A.O., Hansson, L., Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies (2007) Clin Cancer Res, 13 (12), pp. 3536-3544; \n\nLamontagne, K.R., Butler, J., Marshall, D.J., Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models (2006) Mol Cancer Ther, 5 (2), pp. 347-355; \n\nLiu, W.M., Powles, T., Shamash, J., Propper, D., Oliver, T., Joel, S., Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity (2004) Oncogene, 23 (4), pp. 981-990; \n\nMitjavila, M.T., Villeval, J.L., Cramer, P., Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias (1987) Blood, 70 (4), pp. 965-973; \n\nAsano, Y., Okamura, S., Shibuya, T., Harada, M., Niho, Y., Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors (1988) Blood, 72 (5), pp. 1682-1686; \n\nKolonics, A., Apati, A., Nahajevszky, S., Gati, R., Brozik, A., Magocsi, M., Unregulated activation of STAT-5, ERK1/2 and c-Fos may contribute to the phenotypic transformation from myelodysplastic syndrome to acute leukaemia (2001) Haematologia, 31 (2), pp. 125-138; \n\nOhigashi, T., Yoshioka, K., Fisher, J.W., Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells (1996) Life Sci, 58 (5), pp. 421-427; \n\nWestenfelder, C., Baranowski, R.L., Erythropoietin stimulates proliferation of human renal carcinoma cells (2000) Kidney Int, 58 (2), pp. 647-657; \n\nKitamura, T., Tojo, A., Kuwaki, T., Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1 (1989) Blood, 73 (2), pp. 375-380; \n\nNakazawa, M., Mitjavila, M.T., Debili, N., KU 812: A pluripotent human cell line with spontaneous erythroid terminal maturation (1989) Blood, 73 (7), pp. 2003-2013; \n\nvan Zoelen, E.J., Receptor-ligand interaction: A new method for determining binding parameters without a priori assumptions on non-specific binding (1989) Biochem J, 262 (2), pp. 549-556; \n\nPelletier, S., Gingras, S., Funakoshi-Tago, M., Howell, S., Ihle, J.N., Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function (2006) Mol Cell Biol, 26 (22), pp. 8527-8538; \n\nShannon, A.M., Bouchier-Hayes, D.J., Condron, C.M., Toomey, D., Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma (2005) Br J Cancer, 93 (2), pp. 224-232; \n\nFu, P., Jiang, X., Arcasoy, M.O., Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway (2009) Biochem Biophys Res Commun, 379 (3), pp. 696-701; \n\nHardee, M.E., Cao, Y., Fu, P., Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression (2007) PloS One, (6), pp. e549; \n\nDunlop, E.A., Percy, M.J., Boland, M.P., Maxwell, A.P., Lappin, T.R., Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin (2006) Neurodegener Dis, 3 (1-2), pp. 94-100; \n\nUm, M., Lodish, H.F., Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways (2006) J Biol Chem, 281 (9), pp. 5648-5656; \n\nLiang, K., Esteva, F.J., Albarracin, C., Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation (2010) Cancer Cell, 18 (5), pp. 423-435; \n\nMirmohammadsadegh, A., Marini, A., Gustrau, A., Role of erythropoietin receptor expression in malignant melanoma (2010) J Invest Dermatol, 130 (1), pp. 201-210; \n\nArcasoy, M.O., Amin, K., Karayal, A.F., Functional significance of erythropoietin receptor expression in breast cancer (2002) Lab Invest, 82 (7), pp. 911-918; \n\nHamadmad, S.N., Hohl, R.J., Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism (2008) J Pharmacol Exp Ther, 324 (3), pp. 1227-1233; \n\nSinclair, A., Archibeque, I., Zhan, J., Janus kinase (JAK) 2 potency and selectivity assessment of small molecules: Widely used AG490 inhibitor is neither potent nor selective for JAK2 (2011) Blood, 118 (21), p. 4780; \n\nKirken, R.A., Erwin, R.A., Taub, D., Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells (1999) J Leuke Biol, 65 (6), pp. 891-899; \n\nGazit, A., Osherov, N., Posner, I., Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases (1991) J Med Chem, 34 (6), pp. 1896-1907; \n\nJaleel, M., Shenoy, A.R., Visweswariah, S.S., Tyrphostins are inhibitors of guanylyl and adenylyl cyclases (2004) Biochem, 43 (25), pp. 8247-8255; \n\nKaur, G., Gazit, A., Levitzki, A., Stowe, E., Cooney, D.A., Sausville, E.A., Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia (1994) Anticancer Drugs, 5 (2), pp. 213-222; \n\nGewirtz, D.A., Di, X., Walker, T.D., Sawyer, S.T., Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs (2006) Clin Cancer Res, 12 (7 Pt 1), pp. 2232-2238; \n\nFandrey, J., Dicato, M., Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events (2009) Oncologist, (14 SUPPL 1), pp. 34-42; \n\nAmmarguellat, F., Llovera, M., Kelly, P.A., Goffin, V., Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells (2001) Biochem Biophys Res Commun, 284 (4), pp. 1031-1038; \n\nHardee, M.E., Cao, Y., Fu, P., Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression (2007) PloS One, (6), pp. e549; \n\nLester, R.D., Jo, M., Campana, W.M., Gonias, S.L., Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia (2005) J Biol Chem, 280 (47), pp. 39273-39277; \n\nSeidel, H.M., Lamb, P., Rosen, J., Pharmaceutical intervention in the JAK/STAT signaling pathway (2000) Oncogene, 19 (21), pp. 2645-2656; \n\nJatiani, S.S., Baker, S.J., Silverman, L.R., Premkumar, R.E., JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies (2010) Genes Cancer, 1 (10), pp. 979-993; \n\nParganas, E., Wang, D., Stravopodis, D., Jak2 is essential for signaling through a variety of cytokine receptors (1998) Cell, 93 (3), pp. 385-395; \n\nSwift, S., Elliott, S., Sinclair, A., Begley, C.G., Erythropoietin receptor in ovarian cancer cells - Letter (2010) Mol Cancer Ther, 9 (4), pp. 1070-1071; \n\nHsu, R.Y., Chan, C.H., Spicer, J.D., LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis (2011) Cancer Res, 71 (5), pp. 1989-1998; \n\nDoan, H.Q., Bowen, K.A., Jackson, L.A., Evers, B.M., Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells (2009) Anticancer Res, 29 (7), pp. 2473-2478; \n\nKeenan, J., Dooley, M., Pearson, D., Clynes, M., Recombinant human albumin in cell culture: Evaluation of growth-promoting potential for NRK and SCC-9 cells in vitro (1996) Cytotechnology, 24 (243), p. 252; \n\nSlaaby, R., Andersen, A.S., Brandt, J., IGF-I binding to the IGF-I receptor is affected by contaminants in commercial BSA: The contaminants are proteins with IGF-I binding properties (2008) Growth Horm IGF Res, 18 (4), pp. 267-274; \n\nEtherton, T.D., Chung, C.S., Wiggins, J.P., Receptor-dependent and independent degradation of insulin by isolated swine adipocytes at 37 C (1984) J Anim Sci, 59 (2), pp. 366-375; \n\nBlair, K.J., Kiang, A., Wang-Rodriguez, J., Yu, M.A., Doherty, J.K., Ongkeko, W.M., EGF and bFGF promote invasion that is modulated by PI3/Akt kinase and Erk in vestibular schwannoma (2011) Otol Neurotol, 32 (2), pp. 308-314; \n\nHassouna, I., Sperling, S., Kim, E., Erythropoietin augments survival of glioma cells after radiation and temozolomide (2008) Int J Radiat Oncol Biol Phys, 72 (3), pp. 927-934; \n\nLamontagne, K.R., Butler, J., Marshall, D.J., Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models (2006) Mol Cancer Ther, 5 (2), pp. 347-355; \n\nQuesenberry, P., Levin, J., Zuckerman, K., Rencricca, N., Sullivan, R., Tyler, W., Stem cell migration induced by erythropoietin or haemolytic anaemia: The effects of actinomycin and endotoxin contamination of erythropoietin preparations (1979) Br J Haematol, 41 (2), pp. 253-269; \n\nHarmey, J.H., Bucana, C.D., Lu, W., Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion (2002) Int J Cancer, 101 (5), pp. 415-422; \n\nKilleen, S.D., Wang, J.H., Andrews, E.J., Redmond, H.P., Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system (2009) Br J Cancer, 100 (10), pp. 1589-1602; \n\nWang, J.H., Manning, B.J., Wu, Q.D., Blankson, S., Bouchier-Hayes, D., Redmond, H.P., Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism (2003) J Immunol, 170 (2), pp. 795-804; \n\nSugawa, M., Fukui, H., Effects of recombinant human erythropoietin on the growth of various human tumor cells (2005) Biotherapy, 19 (2), pp. 181-196; \n\nBauer, E., Danhauser-Riedl, S., De, R.W., Effects of recombinant human erythropoietin on clonogenic growth of primary human tumour specimens in vitro (1992) Eur J Cancer, 28 A (10), p. 1769; \n\nMiller, C.P., Valliant-Saunders, K., Blau, C.A., Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression (2010) Clin Transl Oncol, 3 (3), pp. 176-180; \n\nYasuda, Y., Musha, T., Tanaka, H., Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice (2001) Br J Cancer, 84 (6), pp. 836-843; \n\nYarkoni, E., Goren, M.B., Rapp, H.J., Regression of a transplanted guinea pig hepatoma after intralesional injection of an emulsified mixture of endotoxin and mycobacterial sulfolipid (1979) Infect Immun, 24 (2), pp. 357-362; \n\nVilleval, J.L., Mitjavila, M.T., Dusanter-Fourt, I., Wendling, F., Mayeux, P., Vainchenker, W., Autocrine stimulation by erythropoietin (Epo) requires Epo secretion (1994) Blood, 84 (8), pp. 2649-2662; \n\nRasko, J.E., Metcalf, D., Gough, N.M., Begley, C.G., The cytokine receptor repertoire specifies autocrine growth factor production in factor-dependent cells (1995) Exp Hematol, 23 (5), pp. 453-460; \n\nPalumbo, C., Battisti, S., Carbone, D., Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed (2008) Cancer Chemother Pharmacol, 61 (5), pp. 893-901; \n\nAcs, G., Chen, M., Xu, X., Acs, P., Verma, A., Koch, C.J., Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells (2004) Cancer Lett, 214 (2), pp. 243-251; \n\nKumar, S.M., Acs, G., Fang, D., Herlyn, M., Elder, D.E., Xu, X., Functional erythropoietin autocrine loop in melanoma (2005) Am J Pathol, 166 (3), pp. 823-830; \n\nSchooley J, Eastment C. Erythropoietin, an autocrine regulator? Serum-free production of erythropoietin by cloned erythroid cell lines (1986) Blood, 68 (1), pp. 263-268. , Hankins WD; \n\nQian, R.L., Chin, K., Kim, J.K., Chin, H.M., Cone, J., Hankins, W.D., Purification of murine erythropoietin produced in serum-free cultures of erythroleukemia cells (1986) Blood, 68 (1), pp. 258-262; \n\nMitjavila, M.T., Le Couedic, J.P., Casadevall, N., Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro (1991) J Clin Lnvest, 88 (3), pp. 789-797; \n\nSherwood, J.B., Shouval, D., Continuous production of erythropoietin by an established human renal carcinoma cell line: Development of the cell line (1986) Proc Natl Acad Sci U S A, 83 (1), pp. 165-169; \n\nShouval, D., Sherwood, J.B., Production of erythropoietin by an established human renal carcinoma cell line: In vitro and in vivo studies (1988) Adv Exp Med Biol, 241, pp. 319-328; \n\nHammond, D., Winnick, S., Paraneoplastic erythrocytosis and ectopic erythropoietins (1974) Ann N Y Acad Sci, 230, pp. 219-227; \n\nKaelin Jr., W.G., The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer (2008) Nat Rev Cancer, 8 (11), pp. 865-873; \n\nBerdel, W.E., Danhauser-Riedl, S., Oberberg, D., Zafferani, M., Effects of hematopoietic growth factors on malignant nonhematopoietic cells (1992) Semin Oncol, 19 (2 SUPPL 4), pp. 41-45; \n\nHamamori, Y., Samal, B., Tian, J., Kedes, L., Persistent erythropoiesis by myoblast transfer of erythropoietin cDNA (1994) Hum Gene Ther, 5 (11), pp. 1349-1356; \n\nMuramatsu, T., Arakawa, S., Fukazawa, K., In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression (2001) Int J Mol Med, 7 (1), pp. 37-42; \n\nGeudens, I., Gerhardt, H., Coordinating cell behaviour during blood vessel formation (2011) Development, 138 (21), pp. 4569-4583; \n\nWu, H., Lee, S.H., Gao, J., Liu, X., Iruela-Arispe, M.L., Inactivation of erythropoietin leads to defects in cardiac morphogenesis (1999) Development, 126 (16), pp. 3597-3605; \n\nKertesz, N., Wu, J., Chen, T.H., Sucov, H.M., Wu, H., The role of erythropoietin in regulating angiogenesis (2004) Dev Biol, 276 (1), pp. 101-110; \n\nDavidoff, A.M., Ng, C.Y., Brown, P., Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice (2001) Clin Cancer Res, 7 (9), pp. 2870-2879; \n\nDepalma, M., Naldini, L., Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis (2006) Biochim Biophys Acta, 1766 (1), pp. 159-166; \n\nZwezdaryk, K.J.,", "hasCitationDuplums" : false, "userChangeableUntil" : "2019-01-31T22:59:00.000+0000", "publishDate" : "2018-05-06T08:59:24.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 18, "ownerInstituteCount" : 74, "directInstituteCount" : 0, "authorCount" : 2, "contributorCount" : 0, "hasQualityFactor" : false, "link" : "/api/publication/27370454", "label" : "Elliott S et al. The effect of erythropoietin on normal and neoplastic cells. (2012) BIOLOGICS-TARGETS & THERAPY 1177-5475 1177-5491 6 163-189", "template" : "